1. Soluble B7-CD28 Family Inhibitory Immune Checkpoint Proteins and Anti-Cancer Immunotherapy
   Muhammad Khan et al, 2021, Frontiers in Immunology CrossRef
2. Real world data in the era of Immune Checkpoint Inhibitors (ICIs): Increasing evidence and future applications in lung cancer
   Giulia Pasello et al, 2020, Cancer Treatment Reviews CrossRef
3. Adverse events of PD-(L)1 inhibitors plus anti-VEGF(R) agents compared with PD-(L)1 inhibitors alone for cancer patients: a systematic review and meta-analysis
   Qiyu Tang et al, 2023, Frontiers in Pharmacology CrossRef
4. Serum immune mediators as novel predictors of response to anti-PD-1/PD-L1 therapy in non-small cell lung cancer patients with high tissue-PD-L1 expression
   Afsheen Raza et al, 2023, Frontiers in Immunology CrossRef
5. Study of the clinicopathological features of soluble PD-L1 in lung cancer patients
   Takanobu Sasaki et al, 2023, Journal of Rural Medicine CrossRef
6. Soluble PD-1: Predictive, Prognostic, and Therapeutic Value for Cancer Immunotherapy
   Muhammad Khan et al, 2020, Frontiers in Immunology CrossRef
7. Myeloid-Derived Suppressive Cells in Ageing and Age-Related Diseases
   Valquiria Bueno et al, 2022, Healthy Longevity and Immune System CrossRef
8. Evolving Dynamic Biomarkers for Prediction of Immune Responses to Checkpoint Inhibitors in Cancer
   Afsheen Raza et al, 2021, Advances in Precision Medicine Oncology CrossRef
9. Prognostic value of soluble programmed cell death ligand-1 (sPD-L1) in lymphoma: a systematic review and meta-analysis
   Yangyang Ding et al, 2023, Annals of Hematology CrossRef
10. ІМУНОГІСТОХІМІЧНА ХАРАКТЕРИСТИКА ГІПЕРПЛАЗІЙ ЕНДОМЕТРІЯ ПОРІВНЯНО ІЗ СЕКРЕТОРНИМ ЕНДОМЕТРІЄМ
    D. A. Khaskhachikh et al, 2024, Актуальні питання педіатрії, акушерства та гінекології CrossRef